Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Raw Materials (2020 - 2025)

Historic Raw Materials for Puma Biotechnology (PBYI) over the last 6 years, with Q3 2025 value amounting to $3.6 million.

  • Puma Biotechnology's Raw Materials rose 162606.64% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 162606.64%. This contributed to the annual value of $7.2 million for FY2024, which is 2617.25% up from last year.
  • Puma Biotechnology's Raw Materials amounted to $3.6 million in Q3 2025, which was up 162606.64% from $6.5 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Raw Materials ranged from a high of $7.2 million in Q4 2024 and a low of $211000.0 during Q3 2024
  • Moreover, its 5-year median value for Raw Materials was $3.7 million (2023), whereas its average is $3.6 million.
  • In the last 5 years, Puma Biotechnology's Raw Materials tumbled by 8374.05% in 2024 and then soared by 162606.64% in 2025.
  • Puma Biotechnology's Raw Materials (Quarter) stood at $4.6 million in 2021, then crashed by 63.25% to $1.7 million in 2022, then soared by 239.07% to $5.7 million in 2023, then increased by 26.17% to $7.2 million in 2024, then crashed by 49.3% to $3.6 million in 2025.
  • Its Raw Materials stands at $3.6 million for Q3 2025, versus $6.5 million for Q2 2025 and $7.1 million for Q1 2025.